Biotricity (NASDAQ:BTCY – Get Free Report) is one of 220 public companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare Biotricity to similar companies based on the strength of its valuation, risk, earnings, analyst recommendations, profitability, dividends and institutional ownership.
Insider & Institutional Ownership
32.5% of Biotricity shares are held by institutional investors. Comparatively, 46.5% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 20.5% of Biotricity shares are held by insiders. Comparatively, 13.7% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Biotricity and its competitors gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Biotricity | $10.60 million | -$18.66 million | -1.29 |
| Biotricity Competitors | $1.19 billion | $59.80 million | 28.58 |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Biotricity and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biotricity | 0 | 0 | 0 | 0 | N/A |
| Biotricity Competitors | 1281 | 3792 | 7904 | 205 | 2.53 |
As a group, “Surgical & medical instruments” companies have a potential upside of 35.84%. Given Biotricity’s competitors higher probable upside, analysts plainly believe Biotricity has less favorable growth aspects than its competitors.
Risk and Volatility
Biotricity has a beta of 2.34, meaning that its stock price is 134% more volatile than the S&P 500. Comparatively, Biotricity’s competitors have a beta of 1.29, meaning that their average stock price is 29% more volatile than the S&P 500.
Profitability
This table compares Biotricity and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biotricity | -163.11% | N/A | -252.90% |
| Biotricity Competitors | -621.59% | -313.05% | -28.63% |
Summary
Biotricity competitors beat Biotricity on 6 of the 10 factors compared.
About Biotricity
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
Receive News & Ratings for Biotricity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotricity and related companies with MarketBeat.com's FREE daily email newsletter.
